New York Governor Hochul signed the Pied-à-Terre Tax Law into law on May 28, 2026, as part of the 2026-2027 New York State Budget. The law, which took effect on July 1,
More
The US Senate confirmed two National Labor Relations Board members on August 7, 2026, reshaping the balance of power at the influential labour regulator. David Prouty, first appointed to the NLRB by
More
Mark Zuckerberg has set out a bold vision for artificial intelligence, arguing that universal access to superintelligent AI could transform the justice system for the better. The Meta Platforms (META) CEO and
More
The legal industry has broadly embraced artificial intelligence, but the pace of adoption is running well ahead of the professional judgment needed to use it responsibly. Comfort with AI tools has grown
More
European equity markets edged lower on Tuesday as a combination of geopolitical risk and disappointing domestic economic data kept investor appetite in check. The FTSE 100 was down 0.08% in early trading,
More
Joby Aviation (JOBY) saw its shares fall roughly 4% as investors reacted cautiously to news of a major defence acquisition and a planned stock sale. The company announced a $500 million defence-related
More
Genuit Group and IWG both fell on the FTSE 250 on Thursday as investors reacted negatively to their respective financial results. Genuit, the sustainable water and climate management solutions group, saw its
More
British retail investors have long turned their backs on domestic equities, but 2026 is shaping up to be a genuine turning point for the UK market. At the end of 2024, domestic
More
Quanterix (QTRX) Names GE Healthcare And Exact Sciences Veteran Jim Gute As Chief Commercial Officer
Quanterix Corporation has appointed medtech veteran Jim Gute as its new chief commercial officer, signalling an ambitious push to accelerate commercial growth. Gute joins Quanterix from Exact Sciences, where he served as
More
Scholar Rock has removed Novo Nordisk’s Catalent manufacturing facility from its FDA submission for apitegromab, a spinal muscular atrophy treatment candidate, following a damaging inspection outcome. The troubled plant received an “Official
More